S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
CVE:LBL

Lattice Biologics Earnings Date, Estimates & History

C$0.05
+0.01 (+11.11 %)
(As of 03/5/2021 01:26 PM ET)
Add
Compare
Today's Range
C$0.05
Now: C$0.05
C$0.05
50-Day Range
C$0.05
MA: C$0.07
C$0.13
52-Week Range
C$0.02
Now: C$0.05
C$0.21
Volume70,000 shs
Average Volume817,984 shs
Market CapitalizationC$6.41 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Earnings

Lattice Biologics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, June 1st, 2021 based off prior year's report dates.

Lattice Biologics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Lattice Biologics (CVE LBL) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
6/1/2021
(Estimated)
       
6/2/2020Q2 2020C($0.01)C($0.01)C$0.62 millionN/A
8/29/2018Q3 2018C($0.01)C($0.01)C$0.25 millionN/A
4/30/2018Q4 2017C($0.01)C($0.01)C$0.50 millionN/A
8/29/2017Q3 2017C($0.01)C($0.01)C$1.03 millionN/A
5/30/2017Q2 2017C($0.03)C($0.03)C$1.18 millionN/A
3/1/2017Q1 2017C($0.03)C($0.03)C$1.19 millionN/A
1/30/2017Q4 2016C($0.03)C($0.03)C$0.96 millionN/A
8/29/2016Q3 2016C($0.04)C($0.04)C$1.25 millionN/A
5/27/2016Q2 2016C($0.04)C($0.04)C$1.38 millionN/A
3/1/2016Q1 2016C($1.29)C($1.29)C$1.38 millionN/A
11/30/2015Q4 2015C($0.06)C($0.06)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.